Pathologists frequently identify amyloid deposits during routine examination of cardiac surgical specimens, especially left atrial appendage tissue excised during cardiac surgery. Historically, clinicians dismissed such findings as benign isolated atrial amyloidosis derived from atrial natriuretic peptide. However, recent evidence reveals that incidental deposits often represent early transthyretin cardiac amyloidosis. Recognizing this underlying pathology allows clinicians to diagnose infiltrative cardiomyopathy before severe ventricular dysfunction develops. Consequently, timely identification alters long-term clinical trajectory and prevents advanced heart failure complications.

Recognizing Transthyretin Cardiac Amyloidosis on Surgical Specimens

Cardiac surgeons often perform left atrial appendage ligation or resection during coronary artery bypass grafting and concomitant arrhythmia procedures. When surgical teams send these resected tissues for routine histopathological evaluation, pathologists may discover congophilic fibrillar aggregates within the myocardial interstitium. In a recently reported clinical scenario, a 70-year-old man underwent coronary artery bypass grafting combined with a MAZE procedure and left atrial appendage ligation for worsening dyspnea, peripheral edema, and atrial fibrillation. Standard histopathological analysis using Congo red staining revealed characteristic apple-green birefringence under polarized light microscopy. Although many practitioners traditionally label atrial deposits as inconsequential age-related phenomena, this case demonstrates that such findings warrant comprehensive diagnostic exploration. Clinicians must recognize that atrial tissue often displays amyloid fibrils before widespread ventricular infiltration becomes obvious on standard echocardiography. Therefore, surgical pathology serves as a crucial early diagnostic alert. Furthermore, failing to pursue these incidental deposits can delay necessary interventions. By treating incidental atrial congophilia as a potential sentinel marker for systemic disease, cardiologists can uncover wild-type transthyretin infiltration at a preclinical or minimally symptomatic stage, markedly improving prognosis.

Diagnostic Journey: From Atrial Appendage Biopsy to Definite Typing

Establishing an accurate diagnosis requires rigorous subtyping because therapeutic pathways diverge substantially based on the specific precursor protein. In the reported index case, pathologists utilized liquid chromatography-tandem mass spectrometry on the Congo red-positive atrial tissue to confirm transthyretin-type amyloid fibrils. Following protein identification, genetic sequencing evaluated the transthyretin gene to differentiate between variant and wild-type forms. Because genetic testing showed no pathogenic mutations, clinicians diagnosed wild-type transthyretin cardiac amyloidosis. To evaluate myocardial burden noninvasively, the clinical team performed technetium-99m pyrophosphate bone scintigraphy, which demonstrated intense myocardial radiotracer uptake consistent with Perugini grade 2 or 3 retention. In addition, serum free light chain assays and immunofixation electrophoresis excluded light-chain amyloidosis, confirming the diagnosis without requiring endomyocardial ventricular biopsy. Consequently, this step-by-step diagnostic workflow highlights the synergy between tissue proteomics, molecular genetics, and nuclear cardiology. When clinicians observe incidental atrial amyloid, they should promptly execute this multimodal algorithm. Moreover, early definitive typing prevents inappropriate treatments and enables prompt initiation of targeted therapeutics. Modern diagnostic pathways ensure that patients receive accurate, disease-specific care rapidly.

Differentiating Isolated Atrial Amyloidosis from Systemic Amyloid Variants

Clinicians must carefully distinguish isolated atrial amyloidosis from systemic amyloid variants such as transthyretin or light-chain amyloidosis. Isolated atrial amyloidosis occurs when atrial myocytes produce excess atrial natriuretic peptide, which deposits locally within the atrial walls due to chronic chamber stretch or aging. Although isolated atrial amyloidosis associates with atrial fibrillation and conduction disturbances, it does not typically cause progressive restrictive cardiomyopathy or extracardiac involvement. In contrast, transthyretin cardiac amyloidosis stems from hepatic synthesis of unstable transthyretin tetramers that dissociate, misfold, and aggregate throughout the cardiovascular system. Over time, transthyretin fibrils infiltrate both ventricles, producing severe diastolic dysfunction, heart failure with preserved ejection fraction, and lethal arrhythmias. Therefore, assuming all atrial amyloid deposits represent benign isolated atrial amyloidosis creates a dangerous diagnostic blind spot. Mass spectrometry and immunohistochemistry provide the precise chemical confirmation necessary to avoid this pitfall. Furthermore, clinicians should remain vigilant for extracardiac red flags such as bilateral carpal tunnel syndrome, spinal stenosis, or biceps tendon rupture. Recognizing these subtle signs helps clinicians correctly interpret surgical pathology and guide appropriate systemic evaluations.

Impact of Disease-Modifying Therapies on Long-Term Outcomes

Historically, medical management of cardiac amyloidosis remained purely supportive, focusing on cautious diuretic therapy for fluid overload. However, the therapeutic landscape has changed dramatically with the development of targeted, disease-modifying agents. In the featured case, the patient initiated treatment with tafamidis alongside spironolactone following successful direct-current cardioversion. Tafamidis binds with high affinity to the thyroxine-binding sites of the transthyretin tetramer, preventing its dissociation into amyloidogenic monomers. Large clinical trials have demonstrated that tafamidis significantly reduces all-cause mortality, cardiovascular hospitalizations, and functional decline in patients with transthyretin cardiomyopathy. Moreover, early initiation delivers the greatest survival benefit, as the drug stabilizes existing proteins but cannot easily remove established myocardial deposits. In addition to tetramer stabilizers, novel therapeutic classes such as transthyretin gene silencers and fibril-depleting monoclonal antibodies are expanding management options. As a result, early histological detection through incidental surgical specimens enables patients to begin life-extending therapy before irreversible biventricular fibrosis occurs. The index patient maintained sinus rhythm and excellent functional stability at his one-year clinical follow-up, illustrating the profound benefit of early therapeutic deployment.

Multidisciplinary Protocols for Incidental Surgical Histopathology

Optimizing outcomes for patients with incidental amyloid deposits requires structured collaboration across surgical, pathology, and cardiology teams. When cardiothoracic surgeons excise atrial appendages during MAZE or valve procedures, standardized tissue handling protocols ensure comprehensive histological assessment. Pathologists should systematically perform Congo red staining whenever tissue architecture appears abnormal or when evaluating older adult surgical cohorts. If polarization reveals amyloid deposits, the pathology team must initiate subtyping via mass spectrometry or refer the tissue to specialized amyloid reference centers. Simultaneously, the surgical team should connect the patient with a specialized heart failure or amyloidosis clinic. Cardiologists then coordinate nuclear scintigraphy, cardiac magnetic resonance imaging, and hematologic screenings to map disease extent. In addition, electrophysiologists must carefully manage concomitant arrhythmias, as atrial amyloidosis frequently triggers recurrent atrial fibrillation and thromboembolism. Thus, establishing an institutional clinical pathway prevents incidental biopsy findings from being overlooked in discharge summaries. Through coordinated multidisciplinary vigilance, healthcare systems can transform an incidental surgical finding into a life-saving diagnostic opportunity for patients with occult amyloid disease.

Frequently Asked Questions

How does atrial amyloid differ from ventricular amyloid deposition?

Atrial amyloid deposits often develop earlier than ventricular deposits or arise independently from local atrial natriuretic peptide secretion. In contrast, ventricular amyloid deposition involves systemic proteins such as transthyretin or immunoglobulin light chains infiltrating the thick myocardium. Ventricular infiltration causes restrictive cardiomyopathy, severe diastolic dysfunction, and progressive biventricular heart failure. Therefore, identifying atrial deposits warrants immediate investigation to determine whether systemic ventricular involvement is actively emerging.

Why is mass spectrometry critical after Congo red staining?

Congo red staining confirms the physical presence of amyloid fibrils through characteristic green birefringence under polarized light, but it cannot identify the specific precursor protein. Liquid chromatography-tandem mass spectrometry provides definitive proteomic typing by analyzing the unique peptide signatures within the microdissected tissue. Accurate typing is essential because treatment strategies for transthyretin amyloidosis differ completely from therapies used for light-chain amyloidosis or localized atrial natriuretic peptide deposits.

When should clinicians order technetium pyrophosphate scintigraphy?

Clinicians should order technetium-99m pyrophosphate scintigraphy whenever they suspect transthyretin cardiac amyloidosis based on unexplained ventricular thickening, heart failure symptoms, or positive atrial histopathology. When combined with negative serum and urine monoclonal protein studies, intense cardiac radiotracer uptake on scintigraphy reliably confirms transthyretin amyloidosis. This validated noninvasive approach frequently eliminates the necessity for invasive endomyocardial ventricular biopsy, expediting the initiation of targeted disease-modifying therapies.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Wright J et al. Incidental Atrial Amyloid on Surgical Pathology Revealing Transthyretin Cardiac Amyloidosis. JACC Case Rep. 2026 Aug 25. doi: undefined. PMID: 42640236.
2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-2891.
3. Kittleson MM, Maurer MS, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. J Am Coll Cardiol. 2023;81(11):1076-1126.